drugset / Trial / NCT03300050

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

NCT03300050 ↗

RandomizedParallel-groupTriple-blindPrevention

Summary

The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost with or without adjuvant.

Timeline

Start
2017-10-10
Primary completion
2018-04-24
Completion
2019-08-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject AS03-adjuvanted cH5/1N1 IIV Vaccine 15 ug Intramuscular
Subject AS03-adjuvanted cH5/1N1 IIV Vaccine 0.5 ml Intramuscular
Subject AS03-adjuvanted cH8/1N1 IIV Vaccine 15 ug Intramuscular
Subject AS03-adjuvanted cH8/1N1 IIV Vaccine 0.5 ml Intramuscular
Subject cH5/1N1 IIV Vaccine 15 ug Intramuscular
Subject cH5/1N1 IIV Vaccine 0.5 ml Intramuscular
Subject cH8/1N1 LAIV Vaccine 0.5 ml Intranasal
Subject cH8/1N1 LAIV Vaccine 3.16228e+07 unknown Intranasal

Indications